Qualitative research to understand the patient experience with advanced and/or metastatic hepatocellular carcinoma
The study provides an in-depth description of signs/symptoms and impacts in advanced and/or metastatic HCC that can support the identification of suitable patient-reported outcome measures. Separate investigation is needed to distinguish between disease impacts and treatment impacts.
Authors
- K. Groot Lipman (ORCID: https://orcid.org/0000-0003-0627-7863)
- Sally Lanar (ORCID: https://orcid.org/0000-0001-6914-9004)
- Benoît Arnould (ORCID: https://orcid.org/0000-0003-3160-5347)
- C. Gousset (ORCID: https://orcid.org/0009-0004-8820-8822)
- Maria Armaou (ORCID: https://orcid.org/0000-0003-1547-253X)
- Asma Kefsi
- Marie de la Cruz (ORCID: https://orcid.org/0000-0002-3343-8960)
- Fallon Jones-Lemmons (ORCID: https://orcid.org/0000-0002-0283-1719)
Institutions
- Sanofi (France) (FR)
- Clinical Insights (US)
- Imperial Consultants (GB)
- Institut National des Sciences Appliquées de Lyon (FR)
Publication Details
- Journal
- Hepatic Oncology
- Published
- 2025-10-23
- DOI
- https://doi.org/10.1080/20450923.2025.2567741
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00